Compare SKT & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKT | ADMA |
|---|---|---|
| Founded | 1981 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | 1994 | 2012 |
| Metric | SKT | ADMA |
|---|---|---|
| Price | $36.01 | $15.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $37.29 | $28.50 |
| AVG Volume (30 Days) | 1.0M | ★ 3.0M |
| Earning Date | 05-27-2026 | 05-15-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.71 | 0.60 |
| Revenue | N/A | ★ $42,219,783.00 |
| Revenue This Year | N/A | $26.71 |
| Revenue Next Year | $5.17 | $21.78 |
| P/E Ratio | $51.86 | ★ $25.99 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $28.69 | $13.76 |
| 52 Week High | $37.95 | $25.67 |
| Indicator | SKT | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 55.81 | 40.86 |
| Support Level | $31.76 | $15.35 |
| Resistance Level | $37.95 | $16.28 |
| Average True Range (ATR) | 0.80 | 0.86 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 50.51 | 32.18 |
Tanger Inc is an owners and operators of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers, with a total gross leasable area of approximately 13.0 million square feet.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.